Results 11 to 20 of about 2,348 (179)

Sonidegib, a Novel Inhibitor of Suicidal Erythrocyte Death [PDF]

Cellular Physiology and Biochemistry, 2018
Background/Aims: The Hedgehog pathway disrupting drug sonidegib is used in the treatment of basal cell carcinoma. Side effects of sonidegib include anemia, which could result either from impaired erythropoiesis or from loss of erythrocytes e.g.
Abdulla Al Mamun Bhuyan, Itishri Sahu, Hang Cao, Florian Lang   +3 more
doaj   +4 more sources

Treatment of basal cell carcinoma with Sonidegib and literature review

Pifu-xingbing zhenliaoxue zazhi
Objective To investigate the efficacy and safety of Sonidegib for basal cell carcinoma. Methods Clinical data and skin histology were analyzed in a patient with ulcerated brown plaque on the nasal dorsum.
Ziyue JIA, Zhe ZHUANG, Xinhui LI, Yongfeng CHEN   +3 more
doaj   +3 more sources

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma [PDF]

Frontiers in Oncology, 2020
Basal cell carcinoma (BCC) accounts for almost 80% of skin cancers, and its healthcare workload burden is substantial within dermatology departments. Although most BCCs are small, well-defined tumors amenable of surgery or conservative procedures, in a ...
Gabriella Brancaccio, Federico Pea, Federico Pea, Elvira Moscarella, Giuseppe Argenziano   +4 more
doaj   +6 more sources

[Artículo traducido] Sonidegib para el tratamiento del carcinoma basocelular avanzado en práctica clínica real: estudio nacional multicéntrico

Actas Dermo-Sifiliográficas, 2023
Resumen: Antecedentes: El carcinoma de células basales (CBC) es el cáncer más prevalente. Una minoría de CBC tiene un comportamiento agresivo (CBCla) y puede requerir inhibidores de la vía hedgehog, como sonidegib como tratamiento.
O.M. Moreno-Arrones, S. Béa-Ardebol, F. Mayo-Martinez, G. Pérez-Pastor, I. Torres-Navarro, M. Bonfill-Ortí, G. Deza, V. Ruiz-Salas, E. Masferrer, C. Feal, L. Turrión-Merino, A. Toll, M. Yébenes, S. Galiano-Mejías, A. Jaka, C. Ferrandiz-Pulido, A. Florez, N. Hernández-Hernández, R. Fernández-de-Misa, L. Rios-Buceta, O. Sanmartin   +20 more
doaj   +4 more sources

Sonidegib reduced tumor burden in patients with advanced basal cell carcinoma in the BOLT trial: Long-term analysis results

EJC Skin Cancer
Background: The Hedgehog inhibitor sonidegib had durable efficacy and a manageable safety profile in patients with locally advanced basal cell carcinoma (laBCC) through 42 months of the BOLT trial.
Aaron S Farberg, Nicholas Squittieri
exaly   +4 more sources

Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study [PDF]

Actas Dermo-Sifiliográficas, 2023
Background: Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment.
O.M. Moreno-Arrones, S. Béa-Ardebol, F. Mayo-Martinez, G. Pérez-Pastor, I. Torres-Navarro, M. Bonfill-Ortí, G. Deza, V. Ruiz-Salas, E. Masferrer, C. Feal, L. Turrión-Merino, A. Toll, M. Yébenes, S. Galiano-Mejías, A. Jaka, C. Ferrandiz-Pulido, A. Florez, N. Hernández-Hernández, R. Fernández-de-Misa, L. Rios-Buceta, O. Sanmartin   +20 more
doaj   +3 more sources

Sonidegib Inhibits the Adhesion of Acute Myeloid Leukemia to the Bone Marrow in Hypoxia: An Optical Tweezer Study [PDF]

Biomedicines
Background: Acute myeloid leukemia (AML) is a heterogeneous disease highly resistant to chemotherapeutic agents. Leukemia stem cells (LSCs) can enter a dormant state and avoid apoptosis in the protective niche of the bone marrow (BM) microenvironment ...
Katarzyna Gdesz-Birula, Sławomir Drobczyński, Krystian Sarat, Kamila Duś-Szachniewicz   +3 more
doaj   +3 more sources

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma [PDF]

Drugs in Context, 2022
Background: Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC).
Antonio J García Ruiz, Nuria García-Agua Soler, Enrique Herrera Acosta, Iris Zalaudek, Josep Malvehy   +4 more
doaj   +2 more sources

Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)

Skin Health and Disease, 2023
Nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome) is a rare genetic condition characterized by the early development of numerous cutaneous basal cell carcinomas (BCCs).
Federico Venturi, Luciana Trane, Flavia Silvestri, Biancamaria Zuccaro, Elisabetta Magnaterra, Vincenzo De Giorgi   +5 more
doaj   +3 more sources

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease

Blood Advances, 2017
: Hedgehog signaling plays a key role in tissue fibrosis, the pathological hallmark of chronic graft-versus-host disease (cGVHD). We conducted a phase 1 trial of sonidegib, a selective antagonist of the hedgehog coreceptor Smoothened, for the treatment ...
Zachariah DeFilipp, Rosalynn M. Nazarian, Areej El-Jawahri, Shuli Li, Jami Brown, Candice Del Rio, Melissa Smith, Betsy Valles, Karen K. Ballen, Steven L. McAfee, Jacalyn Rosenblatt, Joseph H. Antin, Corey S. Cutler, Yi-Bin Chen   +13 more
doaj   +2 more sources